Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
出版年份 2022 全文链接
标题
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
作者
关键词
-
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-16
DOI
10.1186/s10194-022-01415-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
- (2021) Richard B. Lipton et al. HEADACHE
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
- (2021) Messoud Ashina et al. JOURNAL OF HEADACHE AND PAIN
- Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study
- (2021) Lucas Hendrik Overeem et al. CEPHALALGIA
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
- (2020) Ashley Alex et al. HEADACHE
- The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
- (2020) Richard B. Lipton et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
- (2020) Stephen D. Silberstein et al. JOURNAL OF HEADACHE AND PAIN
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- (2020) Theo Vos et al. LANCET
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
- (2020) Fabrizio Vernieri et al. NEUROLOGICAL SCIENCES
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- PND102 BURDEN OF COMORBID DEPRESSION AND ANXIETY ON MIGRAINE-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN ADULT MIGRAINE PATIENTS IN THE UNITED STATES
- (2019) R.B. Lipton et al. VALUE IN HEALTH
- Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class
- (2019) Christian Ziegeler et al. HEADACHE
- Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
- (2018) Messoud Ashina et al. CEPHALALGIA
- The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies
- (2018) Rebecca Burch et al. HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Migraine is first cause of disability in under 50s: will health politicians now take notice?
- (2018) Timothy J. Steiner et al. JOURNAL OF HEADACHE AND PAIN
- Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
- (2018) Todd J. Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom
- (2018) Pamela Vo et al. JOURNAL OF HEADACHE AND PAIN
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- New migraine therapies promise prevention
- (2016) Philip Hunter EMBO REPORTS
- Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- (2013) Daniel Serrano et al. VALUE IN HEALTH
- Panic Disorder and Migraine: Comorbidity, Mechanisms, and Clinical Implications
- (2012) Todd A. Smitherman et al. HEADACHE
- Depression and risk of transformation of episodic to chronic migraine
- (2012) Sait Ashina et al. JOURNAL OF HEADACHE AND PAIN
- Psychiatric comorbidities of episodic and chronic migraine
- (2012) Dawn C. Buse et al. JOURNAL OF NEUROLOGY
- Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population-Based Study
- (2008) Marcelo E. Bigal et al. HEADACHE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started